Rejuveron CEO Confident About Longevity Biotech Prospects In Troubled Economy
Executive Summary
Swiss-based Rejuveron’s diversified platform of longevity biotechs addresses key hallmarks of aging, with the goal of helping people to age better and live longer with reduced burden of age-related diseases. CEO Matthias Steger discusses the firm’s vision and the road ahead.
You may also be interested in...
Newer Therapy Areas Will Drive Women’s Health Funding In 2024
Women’s health startups focusing on areas of high unmet need such as menopause, infertility, preventive care and post-partum care will continue to attract investors in 2024. Meanwhile, machine learning and AI, as well as next-generation treatments such as psychedelic therapy, stand to drive advancements in the space.
News We’re Watching: Boston Scientific Closes Relievant, Medtronic's PFA Earns CE Mark, And More
Medtech Insight's News We're Watching highlights medtech industry news developments you may have missed over the last few weeks.
Smith & Nephew To Acquire CartiHeal For Up To $330M
Smith & Nephew said it will acquire sports medicine technology company CartiHeal for up to $330m to boost its knee injury repair portfolio.